TrialThe oncologist2025

Carelizumab and rivoceranib for advanced extramammary Paget's disease: an investigator-initiated multicenter, single-arm, phase II trial.

Sheng Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.